⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623443 | 0.87 | — | — | |
| SCHEMBL9035438 | 0.85 | — | — | |
| SCHEMBL11669309 | 0.81 | — | — | |
| SCHEMBL7693911 | 0.72 | — | — | |
| SCHEMBL2127211 | 0.72 | — | — | |
| SCHEMBL11042607 | 0.69 | — | — | |
| SCHEMBL17520612 | 0.69 | — | — | |
| SCHEMBL18530217 | 0.69 | — | — | |
| SCHEMBL838994 | 0.67 | — | — | |
| SCHEMBL2571245 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4351570-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347569-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| CN-117715893-A | Combination therapy comprising a MAT2A inhibitor and a PRMT type II inhibitor | 伊迪亚生物科学公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-116903613-A | 2-oxo quinazoline five-membered heterocyclic derivative, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116283799-A | Quinazoline methionine adenosyltransferase 2A inhibitors | 南京正大天晴制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023086934-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TAXANE | IDEAYA BIOSCIENCES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022256808-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | IDEAYA BIOSCIENCES INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256806-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-115260187-A | Pyridone compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115215862-A | Pyrimidone compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |